We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
johanna
sukumar
j.sukumar@imperial.ac.uk
Study
Team
CHAIROS@imperial.ac.uk
Prof
Hashim
Ahmed
hashim.ahmed@imperial.ac.uk
Diseases of male genital organsMalignant neoplasms of male genital organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Prostate biopsy tissue is processed in the laboratory and cut into smaller sections and placed on small glass slides for the pathology doctor to look at under a microscope. The purpose of this study is to carry out a very detailed testing of how well a new artificial intelligence (AI) software is in ruling-out and detecting prostate cancer on high resolution images taken of prostate biopsy tissue.
The study is divided into two stages. The first is the Calibration Stage. This is where we approach patients who have already had prostate biopsies as part of their normal care in the past 24 months to kindly allow us to take high-resolution scans of their biopsy tissue slides. These high resolution images will be looked at by a pathologist who will draw out where all the different types of tissue are such as cancer, atrophy, inflammation, and high grade PIN in addition to any other features. These will then be used to fine-tune the AI software before we run the second Validation Stage.
The Validation Stage will test how accurate the AI software is in 600 patients. Patients who are advised and agreed to have a prostate biopsy will be asked to consider participating. If they agree, and after the biopsies have been taken and processed by the NHS laboratory to create slides, we will take high resolution images of these slides. The AI software will evaluate these slides independently of the pathology doctor and vice versa. We will also ask independent pathologists to also look at the slides. The AI software will be compared to the pathology doctors' reports.
If the AI software is shown to be accurate, then in future, we might be able to use the AI software in the NHS to help pathology doctors and patients.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
• Unwilling or unable to give consent • Any duration or type or dose of androgen deprivation therapy in the 6 months prior to screening • Any prior radiotherapy to the prostate or pelvis (including the prostate) or ablation or chemical treatment of the prostate for treating cancer: these types of treatment affect the anatomy of prostate tissue microstructure for which Galen Prostate AI is not currently validated. NB: any treatment for benign enlargement of the prostate is permitted
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
johanna
sukumar
j.sukumar@imperial.ac.uk
Prof
Hashim
Ahmed
hashim.ahmed@imperial.ac.uk
Study
Team
CHAIROS@imperial.ac.uk
The study is sponsored by Imperial College of Science, Technology and Medicine and funded by NHS ENGLAND .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 49980
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
